Control of stromal keratitis by inhibition of neovascularization
about
Host immune cellular reactions in corneal neovascularizationPotential function of miRNAs in herpetic stromal keratitisClinical correlates of common corneal neovascular diseases: a literature reviewReversible nerve damage and corneal pathology in murine herpes simplex stromal keratitis.In vivo kinetics of GITR and GITR ligand expression and their functional significance in regulating viral immunopathology.DNA containing CpG motifs induces angiogenesis.Herpes keratitis.IL-2/anti-IL-2 antibody complex treatment inhibits the development but not the progression of herpetic stromal keratitis.Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus.Vascular mediators in chronic lung disease of infancy: role of endothelial monocyte activating polypeptide II (EMAP II).Activation of endothelial roundabout receptor 4 reduces the severity of virus-induced keratitis.An anti-inflammatory role of VEGFR2/Src kinase inhibitor in herpes simplex virus 1-induced immunopathology.Degeneration and regeneration of corneal nerves in response to HSV-1 infectionInhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis.Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus.Viruses and autoimmunity.Angiogenesis and lymphangiogenesis-implications for corneal immunity.Activated inflammatory infiltrate in HSV-1-infected corneas without herpes stromal keratitis.Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Who (what) pays toll for the development of herpetic stromal keratitis (HSK).Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1Type I interferon and lymphangiogenesis in the HSV-1 infected cornea - are they beneficial to the host?Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.Long-term consequences of topical dexamethasone treatment during acute corneal HSV-1 infection on the immune system.Colony Stimulating Factor-1 Receptor Expressing Cells Infiltrating the Cornea Control Corneal Nerve Degeneration in Response to HSV-1 Infection.IL-6 Contributes to Corneal Nerve Degeneration after Herpes Simplex Virus Type I Infection.Inhibition of AGS Cancer Cell Proliferation following siRNA-Mediated Downregulation of VEGFR2.The siRNA-Mediated Down-Regulation of Vascular Endothelial Growth Factor Receptor1Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.Application of FGF-2 to modulate herpetic stromal keratitis.Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein.Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer.
P2860
Q26750973-A495C727-1F9C-488A-93A0-ADFDBC0EF8F7Q26823201-F0BB0297-AF14-44B9-8411-C201930D148AQ28257676-089342AF-56CE-43C2-9ED4-5B7AC658B325Q33900294-D0723BAA-1508-489B-A2B5-21108D790920Q33987464-7A221138-E370-4AA9-A4C1-F99861C94E74Q34066361-67C40521-68FC-4EE0-AAEE-8CF88412CF4EQ34297293-AC7CE17D-0604-407C-A8A3-8906FAF9D820Q34749483-A672DDF1-9BB3-4D91-ABF6-6E99A41348EEQ34785842-2B2AE4C8-961D-45D7-9D23-E4AE9A9CE9F7Q34789755-4FA2D40A-0C0B-4413-8DEE-220999368C01Q35037318-0AA18321-FD30-48EE-A3FE-4DBABFD44C24Q35076957-E5DA52B9-EEFD-4758-ABDB-021E979EDE18Q35087668-6A2FC07C-3B2E-4002-973B-FA6DE18D1C56Q35103511-E7ACA380-1D6E-46CC-A062-74E10C8ACC0AQ35956190-BD06BE0A-B17E-494C-903C-9EDBA5847245Q36131519-413C20E1-EF97-4378-945E-0AA170319F74Q36359567-0F3CDC9C-6A77-44E1-BC23-2C8C1CB5578FQ36414187-368E26E5-F493-401D-93C6-E742BA3B1588Q36632237-FA5A9CA6-9957-4FFC-85C7-3974CB5810FFQ36849213-7CFE527A-6466-44B4-9715-44473DC6DEECQ37201594-D7CA1B02-4BB2-48D4-8B85-5948150B7D75Q37466085-E591A81E-CD39-4923-BFB7-14247FA7C91DQ38123280-B6E8AD98-640D-4F4E-8441-5BEF12B13C1CQ38962857-5F313810-3CDE-4749-8D30-E41B72E3403BQ39003450-3C3FC974-2C30-4923-995C-9533521CD43AQ40043246-F4796437-7379-436C-A07A-BA04A903B181Q40585998-EA8C40BE-7C60-4EA3-943B-A56D4D0A03B2Q41015064-289F8013-7DED-42C5-99E7-2966AF62FE4EQ41820460-BEF57BB8-2D22-4C58-9D13-5D0E123A6E6DQ42259034-1E43C4B4-B732-4D83-AD26-BA24A52EA3CDQ43447133-26E22644-A9A0-4A1E-8A55-1B65FDF61482Q44485835-4DAC954F-F864-488C-B58C-468290E14F10Q45360866-2E618865-6192-4304-A94E-78C10ED40361
P2860
Control of stromal keratitis by inhibition of neovascularization
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Control of stromal keratitis by inhibition of neovascularization
@ast
Control of stromal keratitis by inhibition of neovascularization
@en
type
label
Control of stromal keratitis by inhibition of neovascularization
@ast
Control of stromal keratitis by inhibition of neovascularization
@en
prefLabel
Control of stromal keratitis by inhibition of neovascularization
@ast
Control of stromal keratitis by inhibition of neovascularization
@en
P2093
P2860
P1476
Control of stromal keratitis by inhibition of neovascularization
@en
P2093
P2860
P304
P356
10.1016/S0002-9440(10)61777-4
P407
P577
2001-09-01T00:00:00Z